Cabaletta Bio Inc (CABA)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$1.47-3.29%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Cabaletta Bio Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	1.67M
EPS	—	-0.316
Annual ending 2026-12-31
Revenue	—	2.5M
EPS	—	-1.362
Annual ending 2027-12-31
Revenue	—	712,586
EPS	—	-1.199

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Expand clinical development of rese-cel in multiple indications	Cabaletta Bio advances clinical development of rese-cel with positive data.	Intact	clinical development stalls or key trials fail to advance	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Manage and reduce operating expenses	Operating income loss was $44.3M in 2026-Q1, slightly worse than $42.6M in 2025-Q4 but shows management focus.	Broken	operating loss worsens beyond -$44.3M or fails to improve	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. R&D expenses increased from $37.4 million in 2026-Q1 to $44.4 million in 2026-Q2, reflecting clinical development activity. G&A expenses rose modestly from $6.9 million to $7.6 million. Expense trends align with advancing clinical programs, indicating managing operating expenses amid growth. Delivery assessment Oct 24, 2026
Engage in strategic partnerships to enhance growth	Strategic partnerships support growth.	Intact	loss or failure of key partnerships	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPSUnavailable

$-1.42 → Unavailable · observed estimates

FY2027 revenue$0.00B

$0.00B → $0.00B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-1.42	$0	5 / 7
2026-07-25	$-1.42	$0	5 / 7
2026-07-26	$-1.42	$0	5 / 7
2026-07-27	$-1.42	$0	5 / 7
2026-07-28	$-1.42	$0	5 / 7
2026-07-29	$-1.42	$0	5 / 7
2026-07-30	$-1.42	$0	5 / 7
2026-07-31	$-1.24	$712,586	5 / 7
2026-08-01	$-1.42	$0	5 / 7
2026-08-02	$-1.42	$0	5 / 7
2026-08-03	$-1.42	$0	5 / 7
2026-08-04	$-1.42	$0	5 / 7
2026-08-05	$-1.42	$0	5 / 7
2026-08-06	$-1.42	$0	5 / 7
2026-08-07	$-1.24	$712,586	5 / 7
2026-08-08	$-1.24	$712,586	5 / 7
2026-08-09	$-1.42	$0	5 / 7
2026-08-10	$-1.24	$712,586	5 / 7
2026-08-11	$-1.24	$712,586	5 / 7
2026-08-12	$-1.24	$712,586	5 / 7
2026-08-13	$-1.24	$712,586	5 / 7
2026-08-14	$-1.24	$712,586	5 / 7
2026-08-15	$-1.24	$712,586	5 / 7
2026-08-16	$-1.24	$712,586	5 / 7
2026-08-17	$-1.24	$712,586	5 / 7
2026-08-18	$-1.24	$712,586	5 / 7
2026-08-19	$-1.24	$712,586	5 / 7
2026-08-20	$-1.24	$712,586	5 / 7
2026-08-21	$-1.20	$712,586	5 / 7
2026-08-22	$-1.20	$712,586	5 / 7
2026-08-23	$-1.20	$712,586	5 / 7
2026-08-24	$-1.20	$712,586	5 / 7
2026-08-25	$-1.20	$712,586	5 / 7
2026-08-26	$-1.20	$712,586	5 / 7
2026-08-27	$-1.20	$712,586	5 / 7
2026-08-28	$-1.20	$712,586	5 / 7
2026-08-29	$-1.20	$712,586	5 / 7
2026-08-30	$-1.20	$712,586	5 / 7
2026-08-31	$-1.20	$712,586	5 / 7
2026-09-01	$-1.20	$712,586	5 / 7
2026-09-02	$-1.20	$712,586	5 / 7
2026-09-03	$-1.20	$712,586	5 / 7
2026-09-04	$-1.20	$712,586	5 / 7
2026-09-05	$-1.20	$712,586	5 / 7
2026-09-06	$-1.20	$712,586	5 / 7
2026-09-07	$-1.20	$712,586	5 / 7
2026-09-08	$-1.20	$712,586	5 / 7
2026-09-09	$-1.20	$712,586	5 / 7
2026-09-10	$-1.20	$712,586	5 / 7
2026-09-11	$-1.20	$712,586	5 / 7
2026-09-12	$-1.20	$712,586	5 / 7
2026-09-13	$-1.20	$712,586	5 / 7
2026-09-14	$-1.20	$712,586	5 / 7
2026-09-15	$-1.20	$712,586	5 / 7
2026-09-16	$-1.20	$712,586	5 / 7
2026-09-17	$-1.20	$712,586	5 / 7
2026-09-18	$-1.20	$712,586	5 / 7
2026-09-19	$-1.20	$712,586	5 / 7
2026-09-20	$-1.20	$712,586	5 / 7
2026-09-21	$-1.20	$712,586	5 / 7
2026-09-22	$-1.20	$712,586	5 / 7
2026-09-23	$-1.20	$712,586	5 / 7
2026-09-24	$-1.20	$712,586	5 / 7
2026-09-25	Unavailable	$712,586	4 / 7
2026-09-26	Unavailable	$712,586	4 / 7
2026-09-27	Unavailable	$712,586	4 / 7
2026-09-28	Unavailable	$712,586	4 / 7
2026-09-29	Unavailable	$712,586	4 / 7
2026-09-30	Unavailable	$712,586	4 / 7
2026-10-01	Unavailable	$712,586	4 / 7
2026-10-02	Unavailable	$712,586	4 / 7
2026-10-03	Unavailable	$712,586	4 / 7
2026-10-04	Unavailable	$712,586	4 / 7
2026-10-05	Unavailable	$712,586	4 / 7
2026-10-06	Unavailable	$712,586	4 / 7
2026-10-07	Unavailable	$712,586	4 / 7
2026-10-08	Unavailable	$712,586	4 / 7
2026-10-09	Unavailable	$712,586	4 / 7
2026-10-10	Unavailable	$712,586	4 / 7
2026-10-11	Unavailable	$712,586	4 / 7
2026-10-12	Unavailable	$712,586	4 / 7
2026-10-13	Unavailable	$712,586	4 / 7
2026-10-14	Unavailable	$712,586	4 / 7
2026-10-15	Unavailable	$712,586	4 / 7
2026-10-16	Unavailable	$712,586	4 / 7
2026-10-17	Unavailable	$712,586	4 / 7
2026-10-18	Unavailable	$712,586	4 / 7
2026-10-19	Unavailable	$712,586	4 / 7
2026-10-20	Unavailable	$712,586	4 / 7
2026-10-21	Unavailable	$712,586	4 / 7
2026-10-22	Unavailable	$712,586	4 / 7
2026-10-23	Unavailable	$712,586	4 / 7
2026-10-24	Unavailable	$712,586	4 / 7

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	8	2
2026-06-01	8	2
2026-07-01	8	2
2026-08-01	8	2
2026-09-01	8	2
2026-10-01	8	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 8 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Expand clinical development of rese-cel in multiple indicationsDirect metric needs a verified mapping
Manage and reduce operating expensesPublished status: Broken
Engage in strategic partnerships to enhance growthDirect metric needs a verified mapping

Next proof point

Nov 9, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.2%Typical daily move · historical

Downside history

-66.0%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Cabaletta Bio Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

CABA is a high-risk clinical-stage biotechnology company, not an established earnings compounder, and it is loss-making. Its multi-year thesis is in a watch state: management is progressing key trial milestones, but evidence is limited and confidence is low.

What's priced into Cabaletta Bio Inc

The snapshot provides no valuation measure or clear account of market expectations, so whether CABA is cheap or expensive versus peers cannot be assessed. Recent performance is below its industry cohort, while a prior earnings beat and broader Healthcare-sector strength offer some support.

What the fundamentals likely do

Near term, the business remains loss-making, with high risk and a notable chance of a disappointing report; recent financial performance is rated neutral. Over the multi-year view, management reports progress toward rese-cel trial and filing milestones, though outpatient and preconditioning-free development and manufacturing scale-up are mixed.

What Cabaletta Bio Inc hinges on

The thesis hinges on RESET-Myositis data expected in mid-2027 and the planned 2H27 BLA submission, as well as starting the RESET-SSc registrational cohort in 4Q26. It also depends on clinical progress translating into reliable outpatient dosing and scalable supply; weakening jobs data or weaker Healthcare bellweller results could remove sector support.